NEW YORK, March 11, 2013 - vb-news.net, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on CenterPoint Energy, Groupon Inc, Merck & Co.
Inc.(NYSE:CNP - News) has agreed upon forming a master-limited partnership worth $10.7 billion with ArcLight Capital Partners LLC and OGE Energy, a jointly held subsidiary. This deal could herald other utilities to follow suit.
The deal will have storage properties as well as pipelines near shale formations in Arkansas, Louisiana and Texas. Owners of OGE and CenterPoint are planning on an IPO of equity in the agreement. CenterPoint increased the most in over two years and OGE’s shares have gone up the most over four years.
Is CNP a Buy at New Highs? Find Out Here http://vbtrendreport.com/aw/?code=CNP
MLPs, master-limited partnerships, do not pay federal income taxes and distribute the majority of their ready cash to their unit owners. More enterprises are including assets into mergers, enabling them to maintain control while taking advantage of the tax-sheltered arrangement.The transaction is supposed to close sometime during the third quarter. OGE and CenterPoint will evenly
divide authority of the general partner of the new unit. CenterPoint will own 59% interest in the agreement, while OGE will have 28% interest. ArcLight will be the owner of 13% interest.
Shares of CNP soared 8% to $23.61. In other news, Bill Miller, an
Has GRPN Reached The Bottom and Ready To Hit $8? Get Free Trend Analysis Here http://vbtrendreport.com/aw/?code=GRPNGroupon’s shares are trading up 40 cents at $5.48. Miller appreciated the work of
the former CEO of Groupon, Andrew Mason. Miller finds the coast for Groupon
clear, since the company has $1.2 billion in cash and zero debt. He feels that Groupon has a massive addressable market and that the opportunities at the company are great. Miller is expecting the take rates to shoot up once again during this quarter.When Miller was prompted by the hosts at CNBC that he does not have a reputation for investing in stocks like Groupon, he replied that the world changes.
On Friday, Merck & Co., Inc.(NYSE:MRK - News) said that the regulators of the United States have delayed a decision regarding whether to approve a drug that has already been rejected once. This drug would enable anesthetized patients to wake up after surgery.
Get Free Trend Analysis On MRK Here http://vbtrendreport.com/aw/?code=MRK
According to the third-biggest drugmaker in the world, the Food and Drug Administration has sent a notice to the company that it would require an additional three months in order to review the research data. In the month of January, Merck had stated that it was expecting the ruling of the Food and Drug Administration in the first half of this year. Now the company says that the decision might be given in the second half of the year.
vb-news.net’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
The assembled information disseminated by vb-news.net is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vb-news.net does expect that investors will buy and sell securities based on information assembled and presented in vb-news.net. PLEASE always do your own due diligence, and consult your financial advisor.
1419 Westwood Blvd Los Angeles, CA